Results 161 to 170 of about 21,152 (196)
Some of the next articles are maybe not open access.
MUC1 Expression in Hemopoietic Tissues
Journal of Hematotherapy & Stem Cell Research, 2000409 To the editor: The specificity of detection of disseminated cancer by reverse transcriptase polymerase chain reaction (RT-PCR) amplification of so-called tissue-specific genes has been discussed controversially. Dent et al. described in a recent paper the expression of MUC1 by hemopoietic cells of different origin.
W, Krüger, N, Kröger, A R, Zander
openaire +2 more sources
MUC1 immunotherapy is here to stay
Expert Opinion on Biological Therapy, 2012Success of HBV vaccines in reducing the incidence of liver cancer, and HPV vaccines in reducing preneoplastic cervical lesions, demonstrate the potential of cancer reduction by harnessing the immune system. For most human cancers, infectious etiology is not known but other tumor antigens, candidates for vaccines, have been identified.The authors ...
Takashi, Kimura, Olivera J, Finn
openaire +2 more sources
Bortezomib resistance and MUC1 in myeloma
Blood, 2014In this issue of Blood , Yin et al make the novel discovery that targeting the mucin 1 C-terminal subunit (MUC1-C) oncoprotein reverses resistance to the proteasome inhibitor bortezomib in multiple myeloma cells by triggering depletion of glutathione (GSH) pools and induction of oxidative injury.
openaire +2 more sources
Synthesis of MUC1–lipopeptide chimeras
Chemical Communications, 2010An efficient method for the convergent assembly of MUC1-lipopeptide vaccine candidates is described. Chimeras consisting of MUC1 glycopeptides (bearing multiple copies of the T(N) and T tumour-associated carbohydrate antigens) tethered to the lipopeptide immunoadjuvant Pam(3)CysSer were synthesised in high yields using a fragment-based condensation ...
Brendan L, Wilkinson +3 more
openaire +2 more sources
Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model.
Cancer research, 1998The human epithelial mucin, MUC1, is a large transmembrane glycoprotein that is expressed on most simple epithelia. It is overexpressed and aberrantly glycosylated on many human epithelial tumors, including more than 90% of human breast cancers. MUC1 is of interest as an immunotherapy target because patients with breast, ovarian, and pancreatic cancers
G J, Rowse +4 more
openaire +1 more source
MUC1: Structure, Function, and Clinic Application in Epithelial Cancers
International Journal of Molecular Sciences, 2021Shiqing Zhang +2 more
exaly
A review on development of MUC1-based cancer vaccine
Biomedicine and Pharmacotherapy, 2020Tong Gao, Han Lei
exaly